

# CURRICULUM VITAE

## August 2021

### 1. Biographical Information

Name	<b>William Eric Barlow, PhD</b>
Business Address	Cancer Research and Biostatistics 1505 Westlake Ave N, Suite 750 Seattle, WA 98109
Business Telephone	(206) 839-1761
Home Telephone	(206) 365-1982
FAX	(206) 652-4612
Email	<a href="mailto:williamb@crab.org">williamb@crab.org</a>

### 2. Education

Undergraduate	Western Washington University Bellingham, WA BA, Psychology, 1974
Graduate	University of Toronto Toronto, Ontario, Canada MA, Psychology, 1976
	University of Washington Seattle, WA MS, Biostatistics, 1982 PhD, Biostatistics, 1986

### 4. Professional Background

#### Current Position

Senior Biostatistician  
Cancer Research and Biostatistics  
Seattle, WA  
February 2003- present

Research Professor  
Dept. of Biostatistics  
University of Washington  
Seattle, WA  
October 1989 – present (10/89-6/92 Affiliate Assistant Prof;  
7/92-6/93 Affiliate Associate Prof; 7/93-6/99 Research Associate Prof)

Member (Adjunct)  
Fred Hutchinson Cancer Research Center  
Seattle, WA  
2012- present

**Past Positions (in reverse chronological order)**

Scientific Investigator  
Center for Health Studies, Group Health Cooperative  
Seattle, WA  
June 1989 – June 2012 (6/89-6/92 Assistant; 7/92-6/99 Associate)

Adjunct Research Associate Professor and Director of the Biometry Module  
Dept. of Ophthalmology  
University of Washington  
1990-98

Visiting Professor, Biostatistics Dept  
Limburgs University, Diepenbeek Belgium  
March 1995 - June 1995

Assistant Professor and Co-Director of the Biometry Program,  
Division of Biometry, Preventive Medicine,  
University of Southern California, Los Angeles CA  
March 1986 - May 1989

Director, Biometry Module, Doheny Eye Institute  
Los Angeles, CA  
May 1988 - May 1989

Research Fellow  
Department of Epidemiology and Statistics  
Radiation Effects Research Foundation, Hiroshima, Japan,  
October 1982 - May 1984

Instructor of Psychology  
University of Toronto, Scarborough College,  
1977-79; 1975-76

**5. Honors, Awards, Scholarships**

Outstanding Teaching Award  
School of Public Health 1996

School of Public Health Training Grant, 1980-1981  
Cardiovascular Training Grant, 1981-1982, 1984-1986

**6. Professional Activities**

**National scientific committees:**

Chair, Data Safety and Monitoring Committee, OlympiA trial. (Breast International Group sponsored clinical trial) (2014-2021)

Statistician, National Cancer Trials Network Breast Cancer Steering Committee, (2009-2018).

Statistician, National Cancer Trials Network Correlative Core Science Committee, (2019-2021).

Chair, Data Safety and Monitoring Committee, National Eye Institute sponsored clinical trials conducted by the University of California at San Francisco (2005-2021)

Member, Data Safety and Monitoring Committee, National Eye Institute sponsored clinical trials conducted by Johns Hopkins University (2005-2021)

Member, AJCC Cancer Staging, 9th Edition, Breast Chapter, 2020-2021.

Member, Data Safety and Monitoring Committee, “Randomized, double blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2-primary breast cancer”. (French Unicancer sponsored clinical trial) (2014-2016)

Member, AJCC Cancer Staging, 8th Edition, Breast Chapter, 2014-2015.

Member, Data Safety and Monitoring Committee, National Surgical Breast and Bowel Project trial B-41 (2008-2012)

Panel Member, NIH State-of-the-Science Conference: Enhancing Use and Quality of Colorectal Cancer Screening. Feb 2-4, 2010.

Member, ASCO panel, revision of Guidelines for Bisphosphonates in Metastatic Breast Cancer, 2010.

Member, AJCC Cancer Staging, 7<sup>th</sup> Edition, Breast Chapter, 2008-2009.

Member, Planning Committee, National Cancer Institute, Diagnosis and Management of Ductal Carcinoma In Situ conference (2008-2009).

Chair, Data Safety and Monitoring Committee, Pediatric Ophthalmology Trials, National Eye Institute sponsored clinical trials (1997-2005)

Member, Institute of Medicine Committee to Review the Safety and Efficacy of the Anthrax Vaccine, (2000-2002)

Member, Data Safety and Monitoring Committee, Herpetic Eye Disease Trial. (National Eye Institute sponsored clinical trial) (1988-1996)

#### **National statistical committees:**

ASA JSM 2008 Program Committee (2007-2008)

ASA JSM 2004 Program Committee (2003-2004)

ASA Health Policy Section Treasurer (2002-2003)

ASA Joint Meeting Advisory Committee (1998-2000)

ASA Committee on Scientific Freedom & Human Rights (1995-97)

#### **Grant review:**

Ad hoc NIH review (1989, 1996, 1998, 2002, 2005, 2006, 2008, 2010- 2014, 2020)

American Cancer Society – Cancer Control and Prevention section review (2009-2012)

Cancer Prevention Research in Texas, Research Review Committee (2009-2012, 2014-2020)

NIH Special Emphasis Panel, Chair. (2010).

NIH charter member , Health Services Organization and Delivery Study Section (HSOD) (2007-2010)

National Science Foundation (2008)

Department of Defense (2002-2005, 2014, 2015, 2020)

### **Journals:**

Deputy Editor, Clinical Cancer Research (2013-2017)

Editorial board, Journal of Clinical Oncology.

Statistical editor, Journal of the National Cancer Institute.

### **Manuscript review (2012-2021):**

American J Epidemiology, British Journal of Cancer, British Medical Journal, Canadian Journal of Statistics, Cancer Prevention, Clinical Cancer Research, Clinical Trials, JAMA, JAMA Oncology, J Clinical Oncology, JNCI, Ophthalmology, Pathology, The Breast, The Oncologist, Thoracic Oncology, JNCI, Annals of Oncology, Breast Cancer Research & Treatment

### **Society Memberships:**

American Society of Clinical Oncology

Biometric Society (Western North American Region)

### **Local service: Group Health**

Group Health Cooperative Research Committee Chair (acting) (2009-2011)

Group Health Cooperative Human Subjects Review Board (1991-2000)

Group Health Committee on Evaluation of Medical Technology (1992-1996)

Center for Health Studies Biostatistician Search (Chair, 1994-95)

## 7. Bibliography:

### Publications

1. Slamecka NJ, **Barlow W**. The role of surface and semantic features in word repetition effects. *J Verb Learning Behav*, 18:617-627, 1979.
2. **Barlow WE**, Feigl P. Analyzing binomial data with a nonzero baseline using GLIM, Computational Statistics and Data Analysis, 3:201-204, 1985.
3. **Barlow WE**. General relative risk models in stratified epidemiologic studies. App Stat 34:246-257, 1985.
4. Liggett PE, Lean JS, **Barlow WE**, Ryan SJ. Intraoperative argon endo-photocoagulation for recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy, Am J Ophthalmol 103: 146-149, 1987.
5. **Barlow WE**, Prentice, RL. Residuals for relative risk regression models, Biometrika 75: 65-74, 1988.
6. Minckler DS, Heuer DK, Hasty B, Baerveldt G, Cutting RC, **Barlow WE**. Clinical experience with the single-plate Molteno implant in complicated glaucomas, Ophthalmology, 95: 1181-1188, 1988.
7. **Barlow WE**, Sun WH. Bootstrapped confidence intervals for linear relative risk models, Stat Med, 8: 927-935, 1989.
8. Trousdale MD, **Barlow WE**, McGuigan LJB. Assessment of diclofenac on herpes keratitis in rabbit eyes, Arch Ophthalmol, 107: 1664-1666, 1989.
9. **Barlow WE**, Azen SP, and The Silicone Study Group. The effect of therapeutic treatment crossovers on the power of a clinical trial, Control Clin Trials, 11: 314-326, 1990.
10. Liggett PE, Pince KJ, **Barlow W**, Ragen M., Ryan SJ. Ocular trauma in an urban population: Review of 1132 cases, Ophthalmology, 97: 581-584, 1990.
11. Treiman GS, Yellin AE, Weaver FA, **Barlow WE**, Treiman RL, Gaspar MR. An effective treatment protocol for intraarterial drug injection, J Vasc Surg, 12:456-466, 1990.
12. Liggett PE, Gauderman WJ, Moreira CM, **Barlow W**, Green RL, Ryan SJ. Pars plana vitrectomy for acute retinal detachment in penetrating ocular injuries, Arch Ophthalmol, 108:1724-1728, 1990.
13. **Barlow WE**, Lai M, Azen SP. A comparison of methods for computing a stratified kappa, Stat Med, 10:1465-1472, 1991.
14. Azen SP, Boone DC, **Barlow W**, Walonker AF, McCuen B, Anderson MM, Lean JS, Stern WS, Ryan SJ and The Silicone Study Group. Methods, statistical features and baseline results of a standardized, multicentered ophthalmologic surgical trial: The Silicone Study, Control Clin Trials, 12:438-455, 1991.
15. Gauderman WJ, **Barlow WE**. Sample size calculations for ophthalmic studies, Arch Ophthalmol, 110:690-692, 1992.

16. Von Korff M, Deyo RA, Cherkin D, **Barlow W**. Back pain in primary care: Outcomes at 1 year, *Spine*, 18:855-862, 1993.
17. Treiman GS, Yellin AE, Weaver FA, Wang S, Ghalambor N, **Barlow W**, Snyder B, Pentecost MJ. Examination of the patient with a knee dislocation. The case for selective arteriography, *Arch Surg*, 127:1056-62, 1992.
18. Treiman GS, Jenkins JM, Edwards WH Sr, **Barlow W**, Edwards WH Jr, Martin RS 3d, Mulherin JL Jr. The evolving surgical management of recurrent carotid stenosis. *J Vasc Surg*, 16:354-362, 1992.
19. Stone JL, **Barlow WE**, Humayun MS, de Juan E Jr, Milam AH. Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa. *Arch Ophthalmol*, 110:1634-1639, 1992.
20. Curry SJ, Taplin SH, **Barlow WE**, Anderman C, McBride C. A randomized trial of the impact of risk assessment and feedback on participation in mammography screening, *Prev Med* 22:350-360, 1993.
21. Simon GE, VonKorff M, Wagner EH, **Barlow W**. Patterns of antidepressant use in community practice, *Gen Hosp Psychiatry*, 15:399-408, 1993.
22. Bush T, Cherkin D, **Barlow W**. The impact of physician attitudes on patient satisfaction with care for low back pain. *Arch Fam Med*, 2:301-305, 1993.
23. Von Korff M, **Barlow W**, Cherkin D, Deyo RA. Effects of practice style in managing back pain. *Ann Intern Med*, 121:187-195, 1994.
24. **Barlow WE**. Robust variance estimation for the case-cohort design, *Biometrics*, 50:1064-1072, 1994.
25. Thompson RS, **Barlow W**, Taplin SH, Grothaus L, Immanuel V, Salazar A, Wagner EH. A population-based case-cohort evaluation of the efficacy of mammography screening for breast cancer. *Am J Epidemiol*, 140:889-901, 1994.
26. Duerksen KM, **Barlow WE**, Stasior OG. Fused eyelids in premature infants. *Ophthal Plast Reconstr Surg*, 10:234-240, 1994.
27. Kinyoun JL, Zamber RW, Lawrence BS, **Barlow WE**, Arnold AM. Photocoagulation treatment for clinically significant radiation macular edema. *Br J Ophthalmol*, 79:144-149, 1995.
28. Livesey JC, Wiens LW, Von Seggern DJ, **Barlow WE**, Arnold AM. Inhibition of radiation carcinogenesis by WR-77913. *Radiat Res*, 141:99-104, 1995.
29. Simon G, Ormel J, Von Korff M, **Barlow W**. Health care costs associated with depression. *Am J Psychiatry*, 152:352-357, 1995.
30. Simon G, Von Korff M, **Barlow W**. Health care costs of primary care patients with recognized depression. *Arch Gen Psychiatry*, 52:850-856, 1995.
31. Taplin SH, **Barlow W**, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P, Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. *J Natl Cancer Inst*, 87:417-426, 1995

32. Wagner EH, Barrett P, Barry MJ, **Barlow W**, Fowler FJ Jr. The effect of a shared decision-making program on rates of surgery for benign prostatic hyperplasia. Pilot results. Med Care, 33:765-770, 1995.
33. Dionne C, Koepsell TD, Von Korff M, Deyo RA, **Barlow WE**, and Checkoway H. Formal education and back-related disability: In search of an explanation. Spine, 20: 2721-2730, 1995.
34. **Barlow W**. Measurement of interrater agreement with adjustment for covariates. Biometrics, 52: 695-702, 1996.
35. Cherkin DC, Deyo RA, Street JH, Hunt M, **Barlow W**. Pitfalls of patient education: Limited success of a program for back pain in primary care. Spine, 21:345-355, 1996.
36. Cherkin DC, Deyo RA, Street JH, **Barlow W**. Predicting poor outcomes for back pain seen in primary care using patients' own criteria. Spine, 21:2900-2907, 1996.
37. Mills RP, Reynolds A, Emond MJ, **Barlow WE**, and Leen MM. Long-term survival of Moltano glaucoma drainage devices. Ophthalmology, 103:299-305, 1996.
38. Simon GE, VonKorff M, **Barlow W**, Pabiniak C, Wagner E. Predictors of chronic benzodiazepam in a health maintenance organization J Clin Epidemiol, 49:1067-1073, 1996.
39. Kinyoun JL, Lawrence BS, **Barlow WE**. Proliferative radiation retinopathy. Arch Ophthalmol, 114:1097-1100, 1996.
40. Keech PM, Ichikawa L, and **Barlow W**. A prospective study of contact lens complications in a managed care setting. Optom Vis Sci, 73:653-658, 1996.
41. Keech PM, Ichikawa L, and **Barlow W**. Prevalence of contact lens complications. Optometry Today, 24-27, 1996.
42. LeResche L, Saunders K, Von Korff MR, **Barlow W**, and Dworkin SF. Use of exogenous hormones and risk of temporomandibular disorder pain. Pain, 69: 153-160, 1997.
43. Chen RT, Glasser JW, Rhodes PH, Davis RL, **Barlow WE**, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Marcy SM, Ward JI, Wise RP, Wassilak SG, Hadler SC, and the Vaccine Safety Datalink Team. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics, 99:765-773, 1997.
44. **Barlow WE**. Global measures of local influence for proportional hazards regression models. Biometrics, 53:1157-1162, 1997.
45. Dionne C, Koepsell TD, Von Korff M, Deyo RA, **Barlow WE**, and Checkoway H. Predicting long-term disability among back pain patients in primary care settings. J Clin Epidemiol, 50:31-43, 1997.
46. Ballard-Barbash R, Taplin SH, Yankaskas BC, Ernster VL, Rosenberg RD, Carney A, **Barlow WE**, Geller BM, Kerlikowske K, Edwards BK, Lynch CF, Urban N, Chrvla CA, Key CR, Poplack SP, Worden JK, Kessler LG, Breast Cancer

- Surveillance Consortium: a national mammography screening and outcomes database. Am J Roentgenol. 169:1001-1008, 1997.
47. Potosky AL, Merrill RM, Riley GF, Taplin SH, **Barlow W**, Fireman BH, Ballard-Barbash R. Breast cancer survival and treatment in health maintenance organization and fee for service settings. J Natl Cancer Inst, 89:1683-1691, 1997.
  48. Cherkin DC, Wheeler KJ, **Barlow W**, and Deyo, RA. Medication use for low back pain in primary care. Spine, 23:607-614, 1998.
  49. Cherkin DC, Deyo RA, Battie M, Street J, **Barlow W**. A comparison of physical therapy, chiropractic manipulation and provision of an educational booklet for treatment of patients with low back pain. N Engl J Med, 339:1021-1029, 1998.
  50. Teri L, McCurry SM, Buchner DM, Logsdon RG, LaCroix AZ, Kukull WA, **Barlow WE**, Larson EB. Exercise and activity level in Alzheimer's disease: A potential treatment focus. J Rehabil Res Dev, 35:411-419, 1998.
  51. Scholes D, LaCroix AZ, Ott SM, Ichikawa LE, **Barlow WE**. Bone mineral density in young women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol, 93:233-238, 1999.
  52. Potosky AL, Merrill RM, Riley GF, Taplin SH, **Barlow W**, Fireman BH, Lubitz JD. Prostate cancer treatment and 10-year survival among group/staff HMO and fee-for-service medicare patients. Health Serv Res, 34:525-546, 1999.
  53. Merrill RM, Brown ML, Potosky AL, Riley G, Taplin SH, **Barlow W**, Fireman BH. Survival and treatment for colorectal cancer medicare patients in two group/staff health maintenance organizations and the fee-for-service setting. Med Care Res Rev, 56:177-196, 1999.
  54. Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, **Barlow WE**, Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol, 149:521-530, 1999.
  55. Jacobs EJ, White E, Weiss NS, Heckbert SR, LaCroix A, **Barlow W**, Hormone replacement therapy and colon cancer among members of a health maintenance organization. Epidemiology, 10:445-451, 1999.
  56. Tu S-P, Taplin SH, **Barlow WE**, and Boyko EJ. Breast cancer screening by Asian-American women in a managed care environment. Am J Prev Med, 17:55-61, 1999.
  57. Ho, N, Koziol JA, Parsons CL, **Barlow W**, Weiss NS. Natural history of interstitial cystitis in 274 patients receiving sulfated polysaccharide therapy. Urology, 53:1133-1139, 1999.
  58. **Barlow W**, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol, 52:1165-1172, 1999.
  59. Dionne CE, Von Korff M, Koepsell TD, Deyo RA, **Barlow WE**, and Checkoway H. A comparison of pain, functional limitations, and work status indices as outcome measures in back pain research. Spine, 24:2339-2345, 1999.



60. Taplin SH, **Barlow WE**, Ludman E, Maclehose R, Meyers D, Seger D, Herta D, Chin C, Curry S. Testing reminder and motivational telephone calls to increase screening participation. J Natl Cancer Inst.,92:233-242, 2000.
61. Carney PA, Geller BM, Moffett H, Ganger M, Sewell M, **Barlow WE**, Taplin, SH, Sisk C, Ernster VL, Wilke HA, Yankaskas B, Poplack SP Urban N, West MM, Rosenberg, RD, Michael S, Mercurio TD, Ballard-Barbash R. Current medico-legal and confidentiality issues in large multi-center research programs. Am J of Epidemiology, 152: 371-378, 2000.
62. Buist DSM, LaCroix AZ, **Barlow WE**, White E, Cauley JA, Bauer DC, and Weiss NS. Bone mineral density, endogenous hormones, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prevent, 9:235, 2000.
63. LaCroix AZ, Ott SM, Ichikawa L, Scholes S, **Barlow WE**. Low dose hydrochlorothiazide and preservation of bone density in older adults: Results of a three-year randomized controlled trial. Ann Intern Med, 133:516-526, 2000.
64. Fishman P, Taplin S, Meyer D, **Barlow W**. Cost-effectiveness of alternative strategies for increasing participation in a breast cancer screening program. Eff Clin Pract, 3:213-220, 2000.
65. Civic D, Scholes D, Ichikawa L, LaCroix AZ, Yoshida CK, Ott SM, **Barlow WE**. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception, 61:385-390, 2000.
66. Thompson RS, Rivara FP, Thompson DC, **Barlow WE**, Sugg NK, Maiuro RD, Rubanowice DM. Identification and management of domestic violence: a randomized trial. Am J Prev Med. 19:253-63, 2000.
67. Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, **Barlow WE**. Effects of contraceptive use on biochemical markers in young women. J Clin Endocrinol Metab, 86:179-85, 2001.
68. Cherkin DC, Eisenberg D, Sherman KJ, **Barlow W**, Kaptchuk TJ, Street J, Deyo RA. Randomized trial comparing traditional Chinese medical acupuncture, therapeutic massage and self-care education for chronic low back pain. Arch Intern Med, 161:1081-1088, 2001.
69. **Barlow WE**, Taplin ST, Yoshida CK, Buist DS, Seger D, and Brown M. A cost comparison of mastectomy versus breast conserving therapy for early-stage breast cancer. J Natl Cancer Inst, 93:447-455, 2001.
70. Dionne CE, Von Korff M, Koepsell TD, Deyo RA, **Barlow WE**, and Checkoway H. Formal education and backpain: A review. J Epidemiol Community Health, 55:455-468, 2001.
71. Buist DSM, LaCroix AZ, **Barlow WE**, White E, Weiss NS. Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol. 54:417-422, 2001.
72. O'Meara ES, Rossing MA, Daling JR, Elmore JG, **Barlow WE**, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 93:754-762, 2001.

73. **Barlow W**, Davis RL, Glasser J, Rhodes P, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Ward JI, Marcy SM, DeStefano F, Chen RT, Immanuel V, Pearson JA, Vadheim CM, Rebolledo V, Christakis D, Benson PJ, and Lewis N. Risk for first seizure following whole-cell pertussis or measles vaccination. New England Journal of Medicine 345:656-661, 2001.
74. Taplin S, Ichikawa L, Kerlikowske K, Ernster V, Rosenberg R, Yankaskas B, Carney P, Geller B, Urban N, Dignan M, **Barlow W**, Ballard-Barbash R, Sickles E. Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography Radiology. 222:529-535, 2002.
75. Geller BM, **Barlow WE**, Ballard-Barbash R, Ernster V, Yankaskas BC, Sickles EA, Carney PA, Dignan M, Rosenberg R, Urban N, Zheng Y, Taplin S. Use of the American College of Radiology BI-RADS to report on the mammographic evaluation of women with signs and symptoms of breast disease. Radiology 222:536-542, 2002.
76. Chen, C-L, White E, Weiss N, Newcomb P, and **Barlow W**. Hormone replacement therapy in relation to the incidence of the histologic types of breast cancer. JAMA, 287:734-741, 2002.
77. Jackson LA, Yu O, Heckbert SR, Psaty BM, **Barlow WE**, Malais D, Thompson WW, and the Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Amer J Epidemiol, 156:634-640, 2002.
78. **Barlow WE**, Lehman CD, Zheng Y, Ballard-Barbash R, Yankaskas BC, Cutter G, Carney PA, Geller BM, Rosenberg R, Kerlikowske K, Weaver DL, Taplin SH. Performance of diagnostic mammography for women with breast signs or symptoms, J Natl Cancer Inst., 94:1151-1159, 2002.
79. Ernster VL, Ballard-Barbash R, **Barlow WE**, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM. Detection of DCIS in women undergoing screening mammography, J Natl Cancer Inst., 94:1546-1554, 2002.
80. Scholes D, LaCroix AZ, Ichikawa LE, **Barlow WE**, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology, 13:581-587, 2002.
81. Reisch LM, Fosse JS, Beverly K, Yu O, **Barlow WE**, Harris EL, Rolnick S, Barton MB, Geiger AM, Herrinton LJ, Greene SM, Fletcher S, Elmore JG. Training, quality assurance, and assessment of medical record abstraction in a multi-site study, Am J Epidemiol 157:546-51, 2003.
82. Ott S, LaCroix AZ, Ichikawa L, Scholes D, **Barlow WE**. Effect of low-dose thiazide diuretics on plasma lipids: results from a double-blinded, randomized clinical trial in elderly men and women, J Am Geriatr Soc 51:340-7, 2003.
83. Jackson LA, Neuzil KM, Yu O, Benson P, **Barlow WE**, Adams AL, Hanson CA, Mahoney LD, Shay DK, and Thompson WW for the Vaccine Safety Datalink.

- Effectiveness of pneumococcal polysaccharide vaccine in older adults. *N Engl J Med* 348:1747-55, 2003.
84. Geller BM, Kerlikowske K, Carney PA, Abraham LA, Yankaskas BC, Taplin SH, Ballard-Barbash R, Dignan MB, Rosenberg R, Urban N, **Barlow WE**. Mammography surveillance following breast cancer. *Breast Cancer Research and Treatment*, 81:107-115, 2003.
  85. Newton KM, LaCroix AZ, Heckbert SR, Abraham L, McCulloch D, **Barlow W**. Estrogen therapy and risk of cardiovascular events among women with Type 2 diabetes. *Diabetes Care*, 26:2810-2816, 2003.
  86. Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, **Barlow WE**, and Ott SM. Longitudinal changes in bone density in relation to oral contraceptive use, *Contraception*, 68: 177-182, 2003.
  87. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DSM, **Barlow WE**, Cutter G, Geller BM, Yankaskas BC, Taplin SH, Carney PA. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population, *J Clin Oncol*, 21: 4314-21, 2003.
  88. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, **Barlow WE**, Kukull WA, LaCroix AZ, McCormick WC, Larson EB. Exercise plus behavioral management in patients with Alzheimer disease: A randomized controlled trial. *JAMA*, 290: 2015-2022, 2003
  89. Davis RL, **Barlow W**. Placing the risk of seizures with pediatric vaccines in a clinical context. *Paediatr Drugs*, 5:717-22, 2003.
  90. Scholes D, LaCroix AZ, Ichikawa LE, **Barlow WE**, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. *Contraception*, 69:99-104, 2004.
  91. Miglioretti DL, Rutter CM, Geller BM, Cutter G, **Barlow WE**, Rosenberg R, Weaver DL, Taplin SH, Ballard-Barbash R, Carney PA, Yankaskas BC, Kerlikowske K. Effect of breast augmentation on the accuracy of mammography and cancer characteristics. *JAMA*, 291:442-50, 2004.
  92. Elmore JG, Carney PA, Abraham LA, **Barlow WE**, Egger JR, Fosse JS, Cutter GR, Hendrick RE, D'Orsi CJ, Paliwal P, and Taplin SH. The association between obesity and screening mammography accuracy. *Archives of Internal Medicine*, 164:1140-1147, 2004.
  93. Carney PA, Elmore JG, Abraham LA, Gerrity, MS, Hendrick RE, Taplin SH, **Barlow WE**, Cutter GR, Poplack SP, D'Orsi CJ. Radiologist uncertainty and the interpretation of screening mammography. *Medical Decision Making*, 24:255-264, 2004.
  94. Johnston BD, Huebner CE, Tyll LT, **Barlow WE**, Thompson RS. Expanding developmental and behavioral services for newborns in primary care: Effects on parental well-being, practice, and satisfaction. *Am J Prev Med*. 2004; 26:356-66.

95. Huebner CE, **Barlow WE**, Tyll LT, Johnston BD, Thompson RS. Expanding developmental and behavioral services for newborns in primary care: Program design, delivery, and evaluation framework. *Am J Prev Med.* 2004;26:344-55.
96. Taplin SH, Ichikawa L, Yood MU, Manos MM, Geiger AM, Weinmann S, Gilbert J, Mouchawar J, Leyden WA, Altaras R, Beverly RK, Casso D, Westbrook EO, Bischoff K, Zapka JG, **Barlow WE**. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? *J Natl Cancer Inst.* 2004; 96:1518-27.
97. **Barlow WE**, Chi C, Carney PA, Taplin SH, D'Orsi C, Cutter G, Hendrick RE, Elmore, JG. Accuracy of screening mammography interpretation by characteristics of radiologists. *J Nat Cancer Inst.* 2004; 96: 1840-1850.
98. White E, Miglioretti DL, Yankaskas BC, Geller BM, Rosenberg RD, Kerlikowske K, Saba L, Vacek PM, Carney PA, Buist DS, Oestreicher N, **Barlow W**, Ballard-Barbash R, Taplin SH. Biennial versus annual mammography and the risk of late-stage breast cancer. *J Natl Cancer Inst.* 2004;96:1832-1839.
99. Yankaskas BC, Taplin SH, Ichikawa L, Geller BM, Rosenberg RD, Carney PA, Kerlikowske K, Ballard-Barbash R, Cutter G, **Barlow WE**. Association between mammography timing and measures of screening performance in the U.S. *Radiology*, 2005; 234:363-373.
100. Hendrick RE, Cutter GR, Berns EA, Nakano C, Egger J, Carney PA, Abraham L, Taplin SH, D'Orsi CJ, **Barlow W**, Elmore JG. Community-based mammography practice: services, charges, and interpretation methods. *American Journal of Roentgenology* 2005; 84: 433-438.
101. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, **Barlow WE**, Schubert EK, Mankoff DA. Residual tumor uptake of [(99m)Tc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. *Cancer* 2005; 103: 680-688.
102. Kerlikowske K, Smith-Bindman R, Abraham L, Lehman C, Yankaskas BC, Ballard-Barbash R, **Barlow WE**, Voeks J, Geller BM, Carney PA, Sickles EA. Breast cancer yield for examinations recommended for short interval follow-up after screening mammography views only versus after full diagnostic imaging work-up. *Radiology* 2005; 234:684-692.
103. Scholes D, LaCroix AZ, Ichikawa LE, **Barlow WE**, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. *Arch Pediatr Adolesc Med.* 2005;159:139-44.
104. Geiger AM, Yu O, Herrinton LJ, **Barlow WE**, Harris EL, Rolnick S, Barton MB, Elmore JG, Fletcher SW. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. *Arch Intern Med.* 2005;165:516-520.
105. Zheng YY, **Barlow WE**, Cutter G. Assessing accuracy of mammography in the presence of verification bias and intrareader correlation. *Biometrics* 2005; 61:259-268.

106. D'Orsi C, Tu SP, Nakano C, Carney PA, Abraham LA, Taplin SH, Hendrick RE, Cutter GR, Berns E, **Barlow WE**, Elmore JG. The current realities of delivering mammography in the community: Do challenges with staffing & scheduling exist? *Radiology* 2005; 235:391-395.
107. Egger JR, Cutter GR, Carney PA, Taplin SH, **Barlow WE**, Hendrick RE, D'Orsi CJ, Fosse JS, Abraham L, Elmore JG. Mammographer's perception of women's breast cancer risk. *Medical Decision Making* 2005; 25:283-289.
108. Elmore JG, Taplin SH, **Barlow WE**, Cutter GR, D'Orsi C, Hendrick RE, Abraham L, Fosse J, Carney PA. Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography. *Radiology* 2005; 236:37-46.
109. Elmore JG, Reisch LM, Barton MB, **Barlow WE**, Rolnick S, Harris EL, Herrinton LJ, Geiger AM, Beverly RK, Hart G, Yu O, Greene SM, Weiss NS, Fletcher SW. Efficacy of breast cancer screening in the community according to risk level. *J Natl Cancer Inst* 2005; 97:1035-1043.
110. Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA, **Barlow W**, Warren JL, Taplin SH. Explaining black-white differences in receipt of recommended colon cancer treatment. *J Natl Cancer Inst* 2005; 97:1211-20.
111. Herrinton LJ, **Barlow WE**, Yu O, Geiger AM, Elmore, JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW. Efficacy of prophylactic mastectomy in women with unilateral breast cancer. *J Clin Oncol*; 2005; 23: 4275-4286.
112. Weinmann S, Taplin SH, Gilbert J, Beverly RK, Geiger AM, Yood MU, Mouchawar J, Manos MM, Zapka JG, Westbrook E, **Barlow WE**. Characteristics of women with breast cancer who refused follow-up for screening tests or suspicious symptoms. *J Natl Cancer Inst Monogr.* 2005; 2005(35):33-38.
113. Mouchawar J, Taplin S, Ichikawa L, **Barlow WE**, Geiger AM, Weinmann S, Gilbert J, Manos MM, Yood MU. Late stage breast cancer among women with recent negative screening mammography: Do clinical encounters offer opportunity for earlier detection?" . *J Natl Cancer Inst Monogr.* 2005; 2005(35):39-46.
114. Fenton JJ, Barton MB, Geiger AM, Herrinton LJ, Rolnick SJ, Harris EL, **Barlow WE**, Reisch LM, Fletcher SW, Elmore JG. Screening clinical breast examination: How often does it miss lethal breast cancer? *J Natl Cancer Inst Monogr.* 2005; 2005(35):67-71.
115. Paliwal P, Gelfand A, Abraham L, **Barlow W**, Elmore J. Examining accuracy of screening mammography using an event order model. *Stat Med.* 2006; 25:267-283.
116. Weaver DL, Rosenberg RD, **Barlow WE**, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. *Cancer.* 2006;106:732-42.
117. Smith-Bindman R, Miglioretti DL, Lurie N, Abraham L, Barbash RB, Strzelczyk J, Dignan M, **Barlow WE**, Beasley CM, Kerlikowske K. Does utilization of screening

- mammography explain racial and ethnic differences in breast cancer? *Ann Intern Med.* 2006;144:541-53.
118. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, **Barlow W**. Completion of therapy by Medicare patients with stage III colon cancer. *J Natl Cancer Inst.* 2006; 98:610-9.
  119. Fenton JJ, Egger J, Carney PA, Cutter G, D'Orsi C, Sickles EA, Fosse J, Abraham L, Taplin SH, **Barlow W**, Hendrick RE, Elmore JG. Reality check: perceived versus actual performance of community mammographers. *AJR Am J Roentgenol.* 2006; 187:42-6.
  120. Baldwin LM, Klabunde CN, Green P, **Barlow W**, Wright G. In search of the perfect comorbidity measure for use with administrative claims data: Does it exist? *Med Care.* 2006; 44:745-753.
  121. **Barlow WE**, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DSM, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K. Prospective breast cancer risk prediction model for women undergoing screening mammography. *JNCI* 2006; 98:1204-1214.
  122. Geller BM, Ichikawa LE, Buist DSM, Sickles EA, Carney P, Yankaskas BC, Dignan M, Kerlikowske K, Yabroff KR, **Barlow WE**, Rosenberg R. Improving the concordance of mammography assessment and management recommendations. *Radiology.* 2006; 241:67-75.
  123. Rosenberg RD, Yankaskas BC, Abraham L, Sickles EA, Lehman CD, Geller BM, Carney PA, Kerlikowske K, Buist DSM, Weaver DL, **Barlow W**, Ballard-Barbash R. Performance benchmarks for screening performance. *Radiology.* 2006; 241: 55-66.
  124. Porter PL, **Barlow WE**, Yeh I-T, Lin M-G, Yuan X, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes, DF. p27<sup>Kip1</sup> and Cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. *JNCI* 2006; 98: 1723-1731.
  125. Morris A, Baldwin LM, Matthews B, Dominitz JA, **Barlow WE**, Dobie SA, Billingsley KG. Reoperation as a quality indicator in colorectal surgery: A population based analysis. *Annals of Surgery* 2007; 245: 73-79.
  126. Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, **Barlow W**, Wright GE, Baldwin LM. Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship. *Arch Surg.* 2007;142:23-31; discussion 32.
  127. Fenton JJ, Rolnick SJ, Harris EL, Barton MB, **Barlow WE**, Reisch LM, Herrinton LJ, Geiger AM, Fletcher SW, Elmore JG. Specificity of clinical breast examination in community practice. *J Gen Intern Med* 2007; 22:332-337
  128. Fenton, JJ, Taplin SH, Carney PA, Abraham L, Sickles EA, D'Orsi C, Berns EA, Cutter G, Hendrick RE, **Barlow WE**, Elmore JG. Computer-aided detection and interpretive performance of screening mammography. *New England J Med*; 2007, 356:1399-1409.

129. Mankoff DA, O'Sullivan FO, **Barlow WE**, Krohn KA. Molecular imaging research in the outcomes era: Measuring outcomes for individualized cancer therapy. *Academic Radiology*; 2007, 14:398-405.
130. Woodard DB, Gelfand AE, **Barlow WE**, Elmore JG. Performance assessment for radiologists interpreting screening mammography. *Stat in Med*; 2007, 26:1531-1551.
131. Wright GE, **Barlow WE**, Green P, Baldwin L, Taplin SH. Differences among the elderly in the treatment costs of colorectal cancer: How important is race? *Medical Care*; 2007, 45:420-430.
132. Moore HCF, Green SJ, Gralow J, Bearman SI, Lew D, **Barlow WE**, Hudis CA, Wolff AC, Ingle JN, Hortobagyi GN, Livingston RB, Martino S. Intensive dose-dense versus high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. *J Clinical Oncol*; 2007, 25:1677-1682.
133. Hudis CA, **Barlow WE**, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *J Clin Oncol*, 2007; 25:2127-32.
134. Schell MJ, Yankaskas BC, Ballard-Barbash R, Qaqish BF, **Barlow W**, Rosenberg RD, Smith-Bindman R. Evidence-based target recall rates for screening mammography. *Radiology*, 2007; 243:681-689.
135. Cherkin DC, Sherman KJ, Hogeboom CJ, Erro JH, **Barlow WE**, Deyo RA, Avins AL. Efficacy of acupuncture for chronic low back pain: protocol for a randomized controlled trial. *Trials*. 2008; 9:10.
136. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, **Barlow WE**, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. *Ann Intern Med*. 2008; 148:337-47.
137. Billingsley KG, Morris AM, Green P, Dornitz JA, Matthews B, Dobie SA, **Barlow W**, Baldwin LM. Does surgeon case volume influence nonfatal adverse outcomes after rectal cancer resection? *J Am Coll Surg*. 2008; 206:1167-77.
138. Taplin S, Abraham L, **Barlow WE**, Fenton JJ, Berns EA, Carney PA, Cutter GR, Sickles EA, Carl D, Elmore JG. Mammography facility characteristics associated with interpretive accuracy of screening mammography. *J Natl Cancer Inst*. 2008; 100:876-87.
139. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, **Barlow WE**, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. *J Clin Oncol*. 2008; 26:4449-57.
140. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, **Barlow W**, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent

- elderly people: a population-based, nested case-control study. *Lancet*. 372:398-405, 2008.
141. Chew HK, **Barlow WE**, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R. A Phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. *Clin Breast Cancer*. 2008;8:511-5.
  142. Lohsoonthorn V, Kungsadalpipob K, Chanchareonsook P, Limpongsanurak S, Vanichjakkong O, Sutdhibhisal S, Wongkittikraivan N, Sookprome C, Kamolpornwijit W, Jantarasaengaram S, Manotaya S, Siwawej V, **Barlow WE**, Fitzpatrick AL, Williams MA. Is maternal periodontal disease a risk factor for preterm delivery? *Am J Epidemiol*. 2009; 169:731-739.
  143. Cherkin DC, Sherman KJ, Avins AL, Erro JH, Ichikawa L, **Barlow WE**, Delaney K, Hawkes R, Hamilton L, Pressman A, Khalsa PS, Deyo RA. A randomized trial comparing acupuncture, simulated acupuncture and usual care for chronic low back pain, *Arch Intern Med*. 2009; 169:858-866.
  144. Jackson SL, Taplin SH, Sickles EA, Abraham L, **Barlow WE**, Carney PA, Geller B, Berns EA, Cutter GR, Elmore JG. Variability of interpretive accuracy among diagnostic mammography facilities. *J Natl Cancer Inst*. 2009; 101:814-27.
  145. Hershman DL, Unger JM, **Barlow WE**, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology Studies S8814/S8897. *J Clin Oncol*. 2009. 27:2157-2162.
  146. Lohsoonthorn V, Kungsadalpipob K, Chanchareonsook P, Limpongsanurak S, Vanichjakkong O, Sutdhibhisal S, Sookprome C, Wongkittikraivan N, Kamolpornwijit W, Jantarasaengaram S, Manotaya S, Siwawej V, **Barlow WE**, Fitzpatrick AL, Williams MA. Maternal periodontal disease and risk of preeclampsia: a case-control study. *Am J Hypertens*. 2009; 22:457-63.
  147. **Barlow WE**. Overview of methods to estimate the medical costs of cancer. *Medical Care*, 2009, 47(7\_Supplement\_1):S33-S36.
  148. Choi JY, **Barlow W**, Albain K, Hong CC, Blanco J, Livingston R, Davis W, Rae J, Yeh IT, Hutchins L, Ravdin P, Martino S, Lyss A, Osborne CK, Abeloff M, Hayes D. Nitric oxide synthase (NOS3) variants and disease-free survival among treated and untreated breast cancer patients in a SWOG Clinical Trial (S8897), *Clinical Cancer Research* 2009; 15:5258-5266.
  149. Tubbs R, **Barlow WE**, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Outcome of early stage breast cancer patients treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status, *J Clin Oncol*, 2009; 27: 3881-3886.
  150. Sherman KJ, Cherkin DC, Ichikawa I, Avins AL, **Barlow WE**, Khalsa PS, Deyo, RA. Characteristics of patients with chronic back pain who benefit from acupuncture, *BMC Musculoskeletal Disorders*, 10:114, 2009.



151. Ambrosone CB, **Barlow WE**, Reynolds W, Livingston RB, Yeh I-T, Choi J-Y, Davis W, Rae JM, Tang L, Hutchins L, Ravdin P, Martino S, Osborne CK, Abeloff M, Lyss AP, Hayes DF, Albain KS. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early stage breast cancer in SWOG 8897, *J Clin Oncol*, 27:4973-4979, 2009.
152. Albain KS, **Barlow WE**, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Norton L, Lew D, Green SJ, Livingston RB, Martino S, Osborne CK. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial., *Lancet*, 374: 2055-2063, 2009. PMID: 20004966.
153. Albain KS, **Barlow WE**, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, *Lancet Oncology*, 11:55-65, 2010. PMID: 20005174.
154. Harigopal M, **Barlow WE**, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle J, Rimm DL, Hayes DF. Multiplexed assessment of the SWOG 9313 breast cancer trial by AQUA® shows both high and low levels of HER2 are associated with poor outcome. *Am J Pathology*, 176: 1639-1647, 2010. PMID: 20150438; PMCID: PMC2843456.
155. Morris DE, Pepe MS, **Barlow WE**. Contrasting two frameworks for ROC analysis of ordinal ratings. *Med Decis Making*, epub ahead of print, 2010. PMID: 20147599.
156. Steinwachs D, Allen JD, **Barlow WE**, Duncan RP, Egede LE, Friedman LS, Keating NL, Kim P, Lave JR, Laveist TA, Ness RB, Optican RJ, Virnig BA. National Institutes of Health State-of-the-Science Conference Statement: Enhancing Use and Quality of Colorectal Cancer Screening. *Ann Intern Med*. 152:663-667, 2010. PMID: 20388702.
157. Yao S, **Barlow WE**, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. *Breast Cancer Research & Treatment*. 124:433-439, 2010. PMID: 20309628.
158. Taplin SH, Abraham L, Geller BM, Yankaskas BC, Buist DS, Smith-Bindman R, Lehman C, Weaver D, Carney PA, **Barlow WE**. Effect of previous benign breast biopsy on the interpretive performance of subsequent screening Mammography. *J Natl Cancer Inst*. 102:1040-1051, 2010. PubMed PMID: 20601590.
159. Sherman KJ, Cherkin DC, Ichikawa L, Avins AL, Delaney K, **Barlow WE**, Khalsa PS, Deyo RA. Treatment expectations and preferences as predictors of outcome of acupuncture for chronic back pain. *Spine* . 35:1471-7, 2010. PMID: 20535051; PMCID: PMC2895682.

160. Ichikawa LE, **Barlow WE**, Anderson ML, Taplin SH, Geller BM, Brenner RJ; National Cancer Institute-sponsored Breast Cancer Surveillance Consortium. Time trends in radiologists' interpretive performance at screening mammography from the community-based Breast Cancer Surveillance Consortium, 1996-2004. *Radiology*, 256:74-82, 2010. PMID: 20505059.
161. Spangler L, Reid RJ, Inge R, Newton KM, Hujoel P, Chaudhari M, Genco RJ, **Barlow WE**. Cross-sectional study of periodontal care and glycosylated hemoglobin in an insured population. *Diabetes Care*. 33:1753-1758, 2010. PMID: 20504894.
162. Phipps AI, Li CI, Kerlikowske K, **Barlow WE**, Buist DS. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. *Cancer Epidemiol Biomarkers Prev*. 19:1643-54, 2010. PMID: 20501751; PMCID: PMC2882996.
163. Buist DSM, Abraham L, **Barlow WE**, Krishnaraj A, Holdridge RC, Sickles EA, Carney PA, Kerlikowske K, Geller BM for the Breast Cancer Surveillance Consortium. Diagnosis of second breast cancer events after an initial early-stage breast cancer diagnosis. *Breast Cancer Research Treatment*. 124:863-873, 2010. PMID: 20700648.
164. Phipps AI, Buist DSM, Malone KE, **Barlow WE**, Porter PL, Kerlikowske K, Li CI. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. *Breast Cancer Research and Treatment*. *Cancer Causes and Control*. Epub ahead of print, 2010. PMID: 20814817.
165. Yao S, **Barlow WE**, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. *Clinical Cancer Research* 16:6169-6176, 2010. PMID: 21169260.
166. Phipps AI, Buist DS, Malone KE, **Barlow WE**, Porter PL, Kerlikowske K, Li CI. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. *Cancer Causes Control* 22:399-405, 2010. PMID: 21184265.
167. Ellis GK, **Barlow WE**, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. SWOG 0012: A randomized phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant therapy for inflammatory and locally advanced breast cancer. *J Clin Oncol* 29:1014-1021, 2011. PMID: 21220618.
168. Janes H, Pepe MS, Bossuyt PM, **Barlow WE**. Measuring the performance of markers for guiding treatment decisions. *Annals of Internal Medicine* 154:253-259, 2011. PMID: 21320940.
169. Van Poznak CH, Temin S, Yee GC, Janjan NA, **Barlow WE**, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn, JH. American Society of Clinical Oncology Clinical Practice Guideline Update on the Role of Bone Modifying Agents in Metastatic Breast Cancer. *J Clin Oncol*, 2011;29:1221-1227. PMID: 21343561.

170. Fenton JJ, Abraham L, Taplin SH, Geller BM, Carney PA, D'Orsi C, Elmore JG, **Barlow WE**, for the Breast Cancer Surveillance Consortium. Effectiveness of computer-aided detection in community mammography practice. *J National Cancer Institute*, 2011. 103:1152-1161. PubMed PMID: 21795668.
171. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, **Barlow WE**, Tallman M, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EGE, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirel T. High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials *J Clinical Oncology*, 2011. 29:3214-3223. PubMed PMID: 21768471.
172. Sucheston L, Zhao H, Yao S, Zirpoli G, **Barlow WE**, Budd GT, Hershman DL, Davis W, Ciupak G, Stewart J, Isaacs C, Hobday T, Latreille J, Hortobagyi GN, Galow J, Livingston R, Albain K, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity: Results from a SWOG clinical trial for breast cancer. *Breast Cancer Research and Treatment*, 2011. 130:993-1002. PMID: 21766209.
173. Newton KM, Chaudhari M, **Barlow WE**, Inge RE, Theis MK, Spangler LA, Hujuel PP, Reid RJ. A population-based study of periodontal care among those with and without diabetes. *J Periodontol*. 2011. 82:1650-1656. PubMed PMID: 21609255.
174. Livingston R, **Barlow WE**, Kash J, Albain KS, Galow JR, Lew D, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: A Phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. *Breast Cancer Research & Treatment*, 2011. 130:123-131. PMID: 21826527.
175. Phipps AI, Buist DS, Malone KE, **Barlow WE**, Porter PL, Kerlikowske K, O'meara ES, Li CI. Breast density, Body Mass Index, and risk of tumor marker-defined subtypes of breast cancer. *Ann Epidemiol*. 2012. 22:340-8. PubMed PMID: 22366170.
176. Schott AF, **Barlow WE**, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Galow JR, Livingston RB, Hortobagyi GN. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. *Oncologist*. 2012;17:179-87. Epub 2012 Jan 20. PubMed PMID: 22267853.
177. Spangler L, Chaudhari M, **Barlow WE**, Newton KM, Inge R, Hujuel P, Genco RJ, Reid RJ. Using administrative data for epidemiological research: case study to identify persons with periodontitis. *Periodontol* 2000. 2012;58:143-52. PubMed PMID: 22133373.
178. Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Yood MU, **Barlow WE**, Buist DSM. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. *JNCI*. 2012;104:1-10. PMID: 22547340.
179. Mehta RS, **Barlow WE**, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Galow JR, Livingston RB, Hortobagyi GN. Combination

- anastrozole and fulvestrant in metastatic breast cancer. *N Engl J Med*. 2012. 367:435-44. PubMed PMID: 22853014.
180. Chaudhari M, Hubbard R, Reid RJ, Inge R, Newton KM, Spangler L, **Barlow WE**. Evaluating components of dental utilization among adults with diabetes and matched controls via Hurdle models. *BMC Oral Health*. 2012; 12:20. [Epub ahead of print] PubMed PMID: 22776352.
181. Ramsey SD, **Barlow WE**, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. *Contemp Clin Trials*. 2012: S1551-7144(12) 00210-8. [Epub ahead of print] PubMed PMID: 23000081.
182. Wong WB, Ramsey SD, **Barlow WE**, Garrison LP Jr, Veenstra DL. The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007). *Contemp Clin Trials*. 2012; 33:1117-23. PubMed PMID: 22981891.
183. Wirtz HS, Buist DSM, Gralow JR, **Barlow WE**, et al. Frequent antibiotic use and second breast cancer events. *Cancer Epidemiol Biomarkers Prev*, 2013; 22:1588-99. PubMed PMID: 23833124.
184. Yao S, Sucheston LE, Zhao H, **Barlow WE**, et al. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. *Pharmacogenomics J*. 2013 [Epub ahead of print] PubMed PMID: 23999597.
185. Banegas MP, McClure JB, **Barlow WE**, Ubel PA, Smith DM, Zikmund-Fisher BJ, Greene SM, Fagerlin A. Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer. *Patient Educ Couns*. 2013; 91:364-71. PubMed PMID: 23395006.
186. Thariani R, Henry NL, Ramsey SD, Blough DK, **Barlow B**, Gralow JR, Veenstra DL. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. *J Comp Eff Res*. 2013; 2:325-34.
187. Wirtz HS, Boudreau DM, Gralow JR, **Barlow WE**, Gray S, Bowles EJ, Buist DS. Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors. *Breast Cancer Res Treat*. 2014 Feb;143(3):541-50. doi: 10.1007/s10549-013-2816-3. Epub 2014 Jan 10. PubMed PMID: 24407530; PubMed Central PMCID: PMC3935518.
188. Gralow JR, **Barlow WE**, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. *Breast Cancer Res Treat*. 2014;143:351-8. PubMed PMID: 24352574; PubMed Central PMCID: PMC3889983.
189. Beaber EF, Malone KE, Tang MT, **Barlow WE**, Porter PL, Daling JR, Li CI. Oral contraceptives and breast cancer risk overall and by molecular subtype among

- young women. *Cancer Epidemiol Biomarkers Prev.* 2014 May;23(5):755-64. doi: 10.1158/1055-9965.EPI-13-0944. Epub 2014 Mar 14. PubMed PMID: 24633144; PubMed Central PMCID: PMC4032363.
190. Unger JM, **Barlow WE**, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials. *J Natl Cancer Inst.* 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13. PubMed PMID: 24627276; PubMed Central PMCID: PMC3982777.
191. Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, **Barlow WE**, Gralow JR. Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. *J Natl Cancer Inst.* 2014 Apr;106(4):dju034. doi: 10.1093/jnci/dju034. Epub 2014 Mar 13. Review. PubMed PMID: 24627271.
192. Pocobelli G, Newcomb PA, Li CI, Cook LS, **Barlow WE**, Weiss NS. Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. *Breast Cancer Res Treat.* 2014 Jun;145(2):439-47. doi: 10.1007/s10549-014-2911-0. Epub 2014 Mar 27. PubMed PMID: 24671356; PubMed Central PMCID: PMC4056330.
193. Onega T, Beaber EF, Sprague BL, **Barlow WE**, Haas JS, Tosteson AN, D Schnall M, Armstrong K, Schapira MM, Geller B, Weaver DL, Conant EF. Breast cancer screening in an era of personalized regimens: A conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. *Cancer.* 2014 Oct 1;120(19):2955-64. doi: 10.1002/cncr.28771. Epub 2014 May 15. PubMed PMID: 24830599.
194. Smerage JB, **Barlow WE**, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. *J Clin Oncol.* 2014 Jun 2. pii: JCO.2014.56.2561. PubMed PMID: 24888818..
195. Beaber EF, Buist DS, **Barlow WE**, Malone KE, Reed SD, & Li CI (2014). Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. *Cancer Res.* 2014 Aug 1;74(15):4078-89. doi: 10.1158/0008-5472.CAN-13-3400. PubMed PMID: 25085875; PubMed Central PMCID: PMC4154499.
196. Budd GT, Barlow WE, Moore H, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho J, Rinn K, Albain KS, Chew HK, Burton G, Moore TD, Srkalovic G, McGregor B, Flaherty L, Livingston RB, Lew D, Gralow J, & Hortobagyi GN. SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer, *J Clin Oncol.* 2014 Nov 24. pii: JCO.2014.56.3296. [Epub ahead of print] PMID: 25422488
197. Ramsey SD, Henry NL, Gralow JR, Mirick DK, **Barlow W**, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors. *J Clin Oncol.* 2014 Oct 20. pii: JCO.2014.55.5409. [Epub ahead of print] PubMed PMID: 25332254.

198. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, **Barlow WE**, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015 Mar 5;372(10):923-32. PubMed PMID: 25738668; PubMed Central PMCID: PMC4405231.
199. Unger JM, Hershman DL, Martin D, Etzioni RB, **Barlow WE**, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. *J Natl Cancer Inst*. 2014 Dec 24;107(2). Print 2015 Feb. PubMed PMID: 25540245; PubMed Central PMCID: PMC4326312.
200. Tosteson AN, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP, Doria-Rose VP, Wheeler CM, **Barlow WE**, Bronson M, Garcia M, Corley DA, Haas JS, Halm EA, Kamineni A, Rutter CM, Tosteson TD, Trentham-Dietz A, Weaver DL; PROSPR consortium. Variation in screening abnormality rates and follow-up of breast, cervical and colorectal cancer screening within the PROSPR Consortium. *J Gen Intern Med*. 2016; 31:372-9. PubMed PMID: 26658934; PubMed Central PMCID: PMC4803707.
201. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, **Barlow WE**, Blanke C, Thompson IM, Hussain M. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. *JAMA Oncol*. 2016; 2:453-61. PubMed PMID: 26720308. PubMed Central PMCID: PMC4852142.
202. McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde CN, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, **Barlow WE**, Corley DA, Armstrong K, Doubeni CA; PROSPR consortium. Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. *Am J Prev Med*. 2016; 51:507-12. PubMed PMID: 27132628; PubMed Central PMCID: PMC5030116.
203. Unger JM, **Barlow WE**, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The scientific impact of positive and negative Phase 3 cancer clinical trials. *JAMA Oncol*. 2016; 2:875-81. PubMed PMID: 26967260; PubMed Central PMCID: PMC4945370.
204. Conant EF, Beaber EF, Sprague BL, Herschorn SD, Weaver DL, Onega T, Tosteson AN, McCarthy AM, Poplack SP, Haas JS, Armstrong K, Schnall MD, **Barlow WE**. Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. *Breast Cancer Res Treat*. 2016;156:109-16. PubMed PMID: 26931450.
205. Hertz DL, **Barlow WE**, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. *Br J Clin Pharmacol*. 2016; 81:1134-41. PubMed PMID: 26859101.

206. Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, **Barlow WE**, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. *JNCI*. 2016; 108(12). PubMed PMID: 27565902..
207. Schott AF, **Barlow WE**, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. *Breast Cancer Res Treat*. 2016; 159:87-95. PubMed PMID: 27475087; PubMed Central PMCID: PMC5021222.
208. Sprague BL, Conant EF, Onega T, Garcia MP, Beaber EF, Herschorn SD, Lehman CD, Tosteson AN, Lacson R, Schnall MD, Kontos D, Haas JS, Weaver DL, **Barlow WE**; PROSPR Consortium. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. *Ann Intern Med*. 2016;165:457-464. PubMed PMID: 27428568; PubMed Central PMCID: PMC5050130.
209. Nahleh ZA, **Barlow WE**, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. *Breast Cancer Res Treat*. 2016;158:485-95. PubMed PMID: 27393622; PubMed Central PMCID: PMC4963434.
210. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, **Barlow WE**, Minasian LM, Unger J. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. *J Clin Oncol*. 2016 ; 34:3014-22. PubMed PMID: 27325863; PubMed Central PMCID: PMC5012713.
211. Beaber EF, Tosteson AN, Haas JS, Onega T, Sprague BL, Weaver DL, McCarthy AM, Doubeni CA, Quinn VP, Skinner CS, Zauber AG, **Barlow WE**. Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium. *Breast Cancer Res Treat*. 2016; 160:323-331. PubMed PMID: 27665586.
212. Unger JM, **Barlow WE**, Hershman DL. Measuring the real clinical impact of randomized clinical trials in oncology-Reply: Beyond citation counts. *JAMA Oncol*. 2016;2:1511. PubMed PMID: 27355398.
213. Haas JS, **Barlow WE**, Schapira MM, et al. Primary care providers' beliefs and recommendations and use of screening mammography by their patients. *J Gen Intern Med*. 2017 ; 32:449-457. PubMed PMID: 28070772; PubMed Central PMCID: PMC5377895.
214. Wirtz HS, Calip GS, Buist DSM, Gralow JR, **Barlow WE**, Gray S, Boudreau DM. Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors. *Am J Epidemiol*. 2017; 185:661-672. PubMed PMID: 28338879; PubMed Central PMCID: PMC5394250.
215. Bansal A, Sullivan SD, Hershman DL, Lyman GH, **Barlow WE**, McCune JS, Ramsey SD. A stakeholder-informed randomized, controlled comparative

- effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. *J Comp Eff Res.* 2017; 6:461-470. PubMed PMID: 28686055.
216. Krop I, Ismaila N, Andre F, Bast RC, **Barlow W**, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. *J Clin Oncol.* 2017; 35:2838-2847. PubMed PMID: 28692382.
217. Janes H, Brown MD, Crager MR, Miller DP, **Barlow WE**. Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer. *Contemp Clin Trials.* 2017; 63:30-39. PMC5696084.
218. Chen L, Chubak J, Boudreau DM, **Barlow WE**, Weiss NS, Li CI. Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: A SEER-Medicare analysis. *Cancer Res.* 2017; 77(21):6033-6041. PMC5668156.
219. Chen L, Chubak J, Boudreau DM, **Barlow WE**, Weiss NS, Li CI. Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-Medicare population. *Cancer Epidemiol Biomarkers Prev.* 2017; 26(11):1603-1610. PMC5668179.
220. Van Poznak C, Somerfield MR, **Barlow WE**, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jaggi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. *J Clin Oncol.* 2017; 35(35):3978-3986. PMID: 29035643..
221. Sucheston-Campbell LE, Clay-Gilmour AI, **Barlow WE**, et al. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. *Pharmacogenet Genomics.* 2018; 28(2):49-55. PMC5824720.
222. Sharma P, **Barlow WE**, Godwin AK, et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). *Ann Oncol.* 2018; 29(3):654-660. PMC5888953.
223. Schapira MM, **Barlow WE**, Conant EF, et al. Communication practices of mammography facilities and timely follow-up of a screening mammogram with a BI-RADS 0 assessment. *Acad Radiol.* 2018; S1076-6332(18)30010-2. [Epub ahead of print] PubMed PMID: 29433892.
224. Unger JM, Hershman DL, Till C, Tangen CM, **Barlow WE**, Ramsey SD, Goodman PJ, Thompson IM Jr. Using Medicare claims to examine long-term prostate cancer risk of finasteride in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst.* 2018. [Epub ahead of print] PubMed PMID: 29534197.



225. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, **Barlow WE**, Unger JM. Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. *J Clin Oncol*. 2018 [Epub ahead of print] PubMed PMID: 29584550.
226. Pelekanou V, **Barlow WE**, Nahleh ZA, et al. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. *Mol Cancer Ther*. 2018; 17(6):1324-1331. PubMed PMID: 29588392.
227. McCarthy AM, **Barlow WE**, Conant EF, et al. PROSPR Consortium. Breast cancer with a poor prognosis diagnosed after screening mammography with negative results. *JAMA Oncol*. 2018; 4(7):998-1001. PubMed PMID: 29801067.
228. Unger JM, **Barlow WE**, Tangen CM, et al. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. *Cancer Epidemiol*. 2018; 55:117-122. PubMed PMID: 29936140.
229. Seidman AD, Bordeleau L, Fehrenbacher L, **Barlow WE**, et al. National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. *J Clin Oncol*. 2018 Sep 13;JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print] PubMed PMID: 30212295.
230. Beaber EF, Sprague BL, Tosteson ANA, Haas JS, Onega T, Schapira MM, McCarthy AM, Li CI, Herschorn SD, Lehman CD, Wernli KJ, **Barlow WE**. Multilevel Predictors of Continued Adherence to Breast Cancer Screening Among Women Ages 50-74 Years in a Screening Population. *J Womens Health*. 2018 Nov 27. [Epub ahead of print] PubMed PMID: 30481098.
231. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, **Barlow WE**, Fabian CJ, Minasian LM, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. *J Natl Cancer Inst*. 2018 Oct 27. [Epub ahead of print] PubMed PMID:30371800.
232. **Barlow WE**, Beaber EF, Geller BM, et al. Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium. *J Natl Cancer Inst*. 2019 Jul 11. [Epub ahead of print] PubMed PMID: 31292633.
233. Mehta RS, **Barlow WE**, Albain KS, et al. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. *N Engl J Med*. 2019 Mar 28;380(13):1226-1234. PubMed PMID: 30917258.
234. Beaber EF, Sprague BL, Tosteson ANA, Haas JS, Onega T, Schapira MM, McCarthy AM, Li CI, Herschorn SD, Lehman CD, Wernli KJ, **Barlow WE**. Multilevel Predictors of Continued Adherence to Breast Cancer Screening Among Women Ages 50-74 Years in a Screening Population. *J Womens Health (Larchmt)*. 2019 Aug;28(8):1051-1059. Epub 2018 Nov 27. PubMed PMID: 30481098; PubMed Central PMCID: PMC6703243.

235. Conant EF, **Barlow WE**, Herschorn SD, et al. Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density. *JAMA Oncol.* 2019 May 1;5(5):635-642. PubMed PMID: 30816931; PubMed Central PMCID: PMC6512257.
236. Lowry KP, Trentham-Dietz A, Schechter CB, Alagoz O, **Barlow WE**, et al. Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States. *J Natl Cancer Inst.* 2019 Sep 10. [Epub ahead of print] PubMed PMID: 31503283.
237. Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, Gralow JR, Hortobagyi GN, Smerage JB, **Barlow WE**, Hayes DF. Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. *Clin Cancer Res.* 2019 Jul 29. [Epub ahead of print] PubMed PMID: 31358544.
238. Barzi A, Hershman DL, Till C, **Barlow WE**, et al. JM. Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. *Arch Osteoporos.* 2019 Jul 28;14(1):83. PubMed PMID: 31352608.
239. Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh ZA, Hayes DF, Hortobagyi GN, **Barlow WE**, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. *J Immunother Cancer.* 2019 Apr 10;7(1):88. PubMed PMID: 30967156; PubMed Central PMCID: PMC6457012.
240. Larsen V, **Barlow WE**, Yang JJ, Zet al. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. *Clin Breast Cancer.* 2019 Aug;19(4):225-235.e2. Epub 2019 Mar 6. PubMed PMID: 30928413; PubMed Central PMCID: PMC6667288.
241. Sharma P, **Barlow WE**, Godwin AK, et al. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. *J Clin Oncol.* 2019 Oct 28;JCO1900693. [Epub ahead of print] PubMed PMID: 31657982.
242. Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, **Barlow W**, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. *J Clin Oncol.* 2019 Aug 1;37(22):1956-1964. doi: 10.1200/JCO.19.00945. Epub 2019 May 31. PubMed PMID: 31150316.
243. Gralow JR, **Barlow WE**, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. *J Natl Cancer Inst.* 2020;112(7):698-707. PMID: 31693129; PMCID: PMC7357327.
244. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, **Barlow WE**, et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). *J Clin Oncol.* 2020 Mar 10;38(8):804-814. PMID: 31855498; PMCID: PMC7062457.

245. Woodward WA, **Barlow WE**, Jaggi R, et al. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. *JAMA Oncol.* 2020;6(4):505-511. PMID: 31917424; PMCID: PMC6990911.
246. Hershman DL, Till C, Wright JD, Accordino M, Vaidya R, **Barlow WE**, Ramsey S, Unger JM. Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. *Breast Cancer Res Treat.* 2020;181(2):455-463. Epub 2020 Apr 18. PMID: 32306168.
247. Powles RL, Wali VB, Li X, **Barlow WE**, Nahleh Z, Thompson AM, Godwin AK, Hatzis C, Pusztai L. Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. *Clin Cancer Res.* 2020;26(8):1977-1984. PMID: 31919134; PMCID: PMC7717064.
248. **Barlow WE**, Beaber EF, Geller BM, et al. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. *J Natl Cancer Inst.* 2020;112(3):238-246. PMID: 31292633; PMCID: PMC7073922.
249. Lowry KP, Trentham-Dietz A, Schechter CB, Alagoz O, **Barlow WE**, et al. Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States. *J Natl Cancer Inst.* 2020;112(6):582-589. PMID: 31503283; PMCID: PMC7301096.
250. Unger JM, Blanke CD, LeBlanc M, **Barlow WE**, Vaidya R, Ramsey SD, Hershman DL. Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. *JAMA NetOpen.* 2020;. PMID: 32352530; PMCID: PMC7193331.
251. Gralow JR, **Barlow WE**, Paterson AHG, et al. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. *J Natl Cancer Inst.* 2020 Jul 1; 112(7):698-707. PMID: 31693129; PMCID: PMC7357327.
252. Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, **Barlow WE**, Hortobagyi GN, Gralow JR. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). *Support Care Cancer.* 2021 May; 29(5):2509-2517. Epub 2020 Sep 15. PMID: 32929540; PMCID: PMC7956914.
253. Cannioto RA, Hutson A, Dighe S, McCann W, McCann SE, Zirpoli GR, **Barlow W**, et al. Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. *J Natl Cancer Inst.* 2021;113(1):54-63. PMID: 32239145.
254. Malone C, Buist DSM, Tiro J, **Barlow W**, Gao H, Lin J, Winer RL. Out of reach? Correlates of cervical cancer underscreening in women with varying levels of healthcare interactions in a United States integrated delivery system. *Prev Med.* 2021 Apr;145:106410. Epub 2020 Dec 31. PMID: 33388329.

255. Piccart MJ, Kalinsky K, Gray R, **Barlow WE**, Poncet C, Cardoso F, Winer E, Sparano J. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. *Ann Oncol.* 2021 Sep; 32(9):1077-1082. Epub 2021 May 31. PMID: 34082017.

### **Book chapters**

1. **Barlow WE**. Design of a clinical trial for testing the ability of a continuous marker to predict therapy benefit. Chapter 19 (p. 293-304). In J Crowley & A Hoering (Editors). *Handbook of Statistics in Clinical Oncology*, 3rd Ed. CRC Press, 2012.
2. **Barlow WE** and Cologne JB. Alternative formulation of models in case-control studies. Chapter 11 (p. 207-218). In O. Borgan, NE Breslow, N Chatterjee, MH Gail, A Scott & CJ Wild (Editors). *Handbook of Statistical Methods for Case-Control Studies*, 1st Ed. CRC Press, 2018.

### **Other peer-reviewed reports**

1. The Silicone Study Group. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. *Silicone Study Report 1. Archives of Ophthalmology*, 1992;110:770-9.
2. The Silicone Study Group. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. *Silicone Study Report 2. Archives of Ophthalmology*, 1992;110:780-92.
3. **Barlow W**. Modeling of categorical agreement. In P. Armitage and T. Colton (Eds), *Encyclopedia of Biostatistics*, Volume 1, p. 541-545, Wiley and Sons, 1998.
4. Joellenbeck LM, Zwanziger LL, Durch JS, and Strom BL (Editors). *The Anthrax Vaccine: Is It Safe? Does It Work?* Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-Up Agency, Insitute of Medicine. National Academy Press, 2002.

### **Other published work (not peer-reviewed)**

1. **Barlow WE**, Kodama K, Kato H. Risk factors for myocardial infarction and angina pectoris in a Japanese cohort for the period 1958-1978, Radiation Effects Research Foundation Technical Report, TR8-84, 1984.
2. **Barlow WE**. Comment on Muirhead and Darby, Modelling the relative and absolute risks of radiation-induced cancers. *Journal of the Royal Statistical Society, Series A*, 150:105-106, 1987.
3. **Barlow WE**, Fanchiang SC. An evaluation of residuals for the Cox model, SAS Users Group (SUGI) 14, 1989, 1375-1380.

### **PhD Dissertation**

**Barlow, WE**, Generalized relative risk models in stratified epidemiologic studies. University of Washington, Dept. of Biostatistics, 1986, Advisor: Ross L. Prentice, PhD .

## 9. Research Activities:

### Listing of Grants as PI:

Statistical Coordinating Center for PROSPR  
National Cancer Institute  
Co-PI: William Barlow, PhD (2011-2020)

Statistical Coordinating Center for the Breast Cancer Surveillance Consortium  
National Cancer Institute  
PI: William Barlow, PhD (1995-2005)

Case-Cohort Study of Mammography and Breast Cancer  
National Cancer Institute  
PI: William Barlow, PhD

Risk of Future Breast Cancer among Biopsied Women  
National Cancer Institute  
PI: William Barlow, PhD

## 12. University Service:

Dept. of Biostatistics 2<sup>nd</sup> Year Applied Exam Committee (2016)  
Dept. of Biostatistics Admissions Committee (1996-1998, 2006-2018, 2020)  
Dept. of Biostatistics Dr. Richardson's Promotion Committee - Chair (2008)  
Dept. of Biostatistics EPTEC (Teaching) Committee (1998-2002, 2006)  
Dept. of Biostatistics Student Award Committee (1998-2002)  
Dept. of Biostatistics Dr. Benedetti's Promotion Committee - Chair (2002)  
Dept. of Biostatistics First Year Theory Exam Committee (1994, 2003)  
Dept. of Biostatistics Faculty Search Committee (1989-1992, 2002-2005)

## 15. University Teaching

### Teaching Experience

#### **Biostatistics Dept., University of Washington**

Biost 521: Experimental Design (91, 05)  
Biost 512: Medical Biometry II (93, 94, 95, 00, 01, 02, 04)  
Biost 536: Categorical Data Analysis for Epidemiol. (95, 97, 98, 01, 07, 08)  
Biost 537: Survival Analysis for Epidemiologists (98, 03, 06, 07, 09, 10)

#### **Biostatistics Dept., Limburgs University, Belgium**

Survival Analysis (95)

**Division of Biometry, University of Southern California**

Advanced Statistical Computing (86), Student Consulting (86),  
Clinical Trials Design (87), and Experimental Design (88, 89)

**Psychology Dept., University of Toronto**

Taught introductory statistics and conducted laboratories, 75-79

**16. Mentoring**

**Biostatistics Department, University of Washington**

Chairman, MS Theses

- C. Chi, Factors explaining radiologist variability in mammography performance – Nov 2003
- C. Yoshida, An alternative to Cook's distance for measuring overall influence in the linear model, August 00
- J. Guo, Medical care costs of metastatic breast cancer and costs in the last year of life, August 98
- C. Chin, An evaluation of mammography participation and a randomized intervention to improve utilization, Dec 97
- L. Ichikawa, Random effects and generalized estimating equations approaches to growth curve analysis, March 95

Committee member, PhD

Biostatistics: J Gu, R Jones, M Kulich, D Liu

Epidemiology: C Chen, C Dionne, E Jacobs, J Simpson, D Buist,  
E O'Meara, J Weiss, M Jackson, E Dolan, E Beaver, G Pocobelli,  
A Phipps, V Lohsoonthorn, E Thacker

Health Services: J Graves, J Unger, M Banegas

**Division of Biometry, University of Southern California**

Chairman, MS Theses:

- C. Hackett, Randomization Tests for Repeated Measures Analyses, 1989
- M.Y. Lai, A Comparison of Vitrectomized to Non-Vitrectomized Proliferative Vitreoretinopathy Patients and Comparison of Methods for Calculating a Stratified Kappa Statistic, 1989
- S.P. Fanchiang, Assessing Goodness-of-Fit in the Cox Model by Residual Analysis, 1988

24-Jan-23

W.H. Sun, Bootstrapped Confidence Intervals for the Linear Relative Risk Cox Model, 1987

Co-Chairman, PhD Dissertation (with Stanley Azen, PhD):

D. Bradley, Estimating Relative Risks with Cubic Smoothing Splines, 1989